[1]邓玮玮,朱娅华,范敏,等.99TcmO4-全身显像联合颈胸SPECT/CT在DTC患者术后肺转移灶显影中的应用[J].国际放射医学核医学杂志,2018,(3):207-211.[doi:10.3760/cma.j.issn.1673-4114.2018.03.003]
　Deng Weiwei,Zhu Yahua,Fan Min,et al.Effectiveness of 99Tcm-pertechnetate whole body scan with neck and chest SPECT/CT for the detection of post-surgical pulmonary metastasis in differentiated thyroid carcinoma patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(3):207-211.[doi:10.3760/cma.j.issn.1673-4114.2018.03.003]
点击复制

99TcmO4-全身显像联合颈胸SPECT/CT在DTC患者术后肺转移灶显影中的应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第3期
页码:
207-211
栏目:
单光子显像在临床中的应用
出版日期:
2018-05-25

文章信息/Info

Title:
Effectiveness of 99Tcm-pertechnetate whole body scan with neck and chest SPECT/CT for the detection of post-surgical pulmonary metastasis in differentiated thyroid carcinoma patients
作者:
邓玮玮;  朱娅华;  范敏;  张春银
646000 泸州, 西南医科大学附属医院核医学科
Author(s):
Deng Weiwei;  Zhu Yahua;  Fan Min;  Zhang Chunyin
Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, China
关键词:
甲状腺肿瘤; 肿瘤转移; 99m锝高锝酸钠; 单光子发射计算机体层摄影术
Keywords:
Thyroid neoplasms; Neoplasm metastasis; Sodium pertechnetate Tc 99m; Single photon emission computed tomography computed tomography
DOI:
10.3760/cma.j.issn.1673-4114.2018.03.003
摘要:
目的 探讨99TcmO4-全身显像联合颈胸SPECT/CT在分化型甲状腺癌（DTC）术后肺转移灶检出中的应用。方法 回顾性分析2013年1月至2016年1月收治的34例DTC肺转移患者在术后131I治疗前的99TcmO4-全身显像联合颈胸SPECT/CT中肺转移灶的检出情况，计算99TcmO4-全身显像联合颈胸SPECT/CT检出肺转移灶的灵敏度、阳性预测值，并评估其对治疗决策的影响。结果 34例肺转移患者中，2例表现为阳性（放射性浓聚+结构异常），10例表现为可疑阳性（仅有典型肺转移CT表现），22例表现为可疑阴性，若将可疑阳性与阳性均视为阳性发现，则99TcmO4-全身显像联合颈胸SPECT/CT发现肺转移灶的灵敏度为35.3%（12/34），阳性预测值为100%（12/12），11例患者在后续的131I治疗中增加了剂量。结论 99TcmO4-全身显像联合颈胸SPECT/CT能发现部分无99TcmO4-浓聚的肺转移灶，提高了肺转移灶的检出率；指导临床调整131I治疗剂量，改善预后。
Abstract:
Objective To evaluate the effectiveness of 99Tcm-pertechnetate whole body scan with neck and chest SPECT/CT for detecting post-surgical pulmonary metastasis in differentiated thyroid carcinoma(DTC) patients. Methods A total of 34 DTC patients were evaluated retrospectively. The patients underwent 99Tcm-pertechnetate whole body scan with neck and chest SPECT/CT after surgery and before 131I treatment. The sensitivity and positive predictive value of this imaging in detecting pulmonary metastasis were calculated. Moreover, its impact on formulating therapeutic schedule was analyzed. Results Two of the 34 patients were defined as positive, which was manifested as an anatomical finding from CT with increased radiotracer uptake. Ten patients were equivocal positive, which was manifested as typical abnormal anatomical localization of lung metastasis without radiotracer uptake. The remaining 22 patients were considered as equivocal negative. Considering positive and equivocal results as positive findings, the sensitivity of the 99Tcm-pertechnetate whole body scan with neck and chest SPECT/CT in detecting pulmonary metastasis was 35.3%(12/34), and its positive predictive value was 100%(12/12). Consequently, 11 of 34 patients received increased radioactive dosage in the subsequent 131I treatment. Conclusions Most pulmonary metastasis of DTC manifested as no radiotracer uptake in 99Tcm-pertechnetate planar imaging, and bigger lesions tended to show positive pertechnetate uptake. 99Tcm-pertechnetate whole body scan with neck and chest SPECT/CT could detect several pulmonary metastasis lesions which showed no pertechnetate uptake. Thus, this process can increase the positive detection rate of pulmonary metastasis lesions and adjust the treatment program of some patients.

参考文献/References:

[1] 董峰, 周荫保. 分化型甲状腺癌术后131I清甲效果的影响因素[J]. 国际放射医学核医学杂志, 2010, 34(1):27-31. DOI:10.3760/cma.j.issn.1673-4114.2010.01.007. Dong F, Zhou YB. Influencing factors of radioiodine ablation of post-surgical thyroid remnants in differentiated thyroid carcinoma[J]. Int J Radiat Med Nucl Med, 2010, 34(1):27-31.
[2] 李少林, 王荣福, 张永学, 等. 核医学[M]. 8版. 北京:人民卫生出版社, 2013:267-268. Li SL, Wang RF, Zhang YX, et al. Nuclear Medicine[M]. 8th ed. Beijing:People’s Medical Publishing House, 2013:267-268.
[3] Kalender E, Zeki CY, Elboga U, et al. Lung metastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy[J]. Rev Esp Med Nucl Imagen Mol, 2012, 31(6):328-331. DOI:10.1016/j.remn.2012.04.007.
[4] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1):1-133. DOI:10.1089/thy.2015.0020.
[5] Kueh SS, Roach PJ, Schembri GP. Role of Tc-99m pertechnetate for remnant scintigraphy post-thyroidectomy[J]. Clin Nucl Med, 2010, 35(9):671-674. DOI:10.1097/RLU.0b013e3181e9f917.
[6] Tsai CJ, Cheng CY, Shen DH, et al. Tc-99m imaging in thyroidectomized differentiated thyroid cancer patients immediately before I-131 treatment[J]. Nucl Med Commun, 2016, 37(2):182-187. DOI:10.1097/MNM.0000000000000426.
[7] Verma N, Singh-Wadhwa S, Arvela OM. Metastatic thyroid cancer visualized on technetium pertechnetate and iodine-131 scintigraphy[J]. Clin Nucl Med, 2002, 27(8):610. DOI:10.1097/01.RLU.0000020744.19209.35.
[8] Scott GC, Meier DA, Dickinson CZ. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide[J]. J Nucl Med, 1995, 36(10):1843-1845.
[9] Chantadisai M, Kingpetch K. Usefulness of 99mTc-pertechnetate whole body scan with neck and chest SPECT/CT for detection of post-surgical thyroid remnant and metastasis in differentiated thyroid cancer patients[J]. Ann Nucl Med, 2014, 28(7):674-682. DOI:10.1007/s12149-014-0864-3.
[10] Liu M, Chai L, Luo Q, et al. 99mTc-pertechnetate-avid metastases from differentiated thyroid cancer are prone to benefit from 131I therapy: A prospective observational study[J/OL]. Medicine (Baltimore), 2017, 96(33):e7631[2018-02-04]. https://www.ncbi.nlm.nih.gov/pubmed/28816945. DOI:10.1097/MD.0000000000007631.
[11] Aydin F, Sipahi M, Budak ES, et al. Role of Tc-99m pertechnetate for remnant scintigraphy, post-thyroidectomy, and serum thyroglobulin and antithyroglobulin antibody levels in the patients with differentiated thyroid cancer[J]. Ann Nucl Med, 2016, 30(1):60-67. DOI:10.1007/s12149-015-1031-1.
[12] 陈红, 韩丽, 李飞,等. 99TcmO4-甲状腺显像及融合显像在分化型甲状腺癌术后转移灶显影中的应用[J]. 安徽医学, 2016, 37(1):83-84. DOI:10.3969/j.issn.1000-0399.2016.01.027. Chen H, Han L, Li F, et al. Usefulness of 99Tcm-pertechnetate thyroid scan and SPECT/CT for detection of post-surgical metastasis in differentiated thyroid carcinoma patients[J]. Anhui Med J, 2016, 37(1):83-84.

相似文献/References:

[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
　Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
　Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
　Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[5]张胤,陈跃.18F-氟化钠PET/CT诊断肿瘤骨转移应用进展[J].国际放射医学核医学杂志,2015,39(1):96.[doi:10.3760/cma.j.issn.1673-4114.2015.01.020]
　Zhang Yin,Chen Yue.Application progress of 18F-NaF PET/CT in the diagnosis of neoplasm metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):96.[doi:10.3760/cma.j.issn.1673-4114.2015.01.020]
[6]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
　Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[7]徐金苹,袁德晓,张江虹,等.辐射诱导的外泌体在肿瘤细胞侵袭转移中的作用[J].国际放射医学核医学杂志,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
　Xu Jinping,Yuan Dexiao,Zhang Jianghong,et al.The role of radiation-induced exosomes in tumor invasion and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
[8]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
　Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[9]刘雪辉,李洪均,于鸿煦.SPECT/CT融合显像对可疑骨转移灶的诊断效能[J].国际放射医学核医学杂志,2015,39(3):201.[doi:10.3760/cma.j.issn.1673-4114.2015.03.003]
　Liu Xuehui,Li Hongjun,Yu Hongxu.Diagnostic efficacy of SPECT/CT fusion imaging in assessing possible bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):201.[doi:10.3760/cma.j.issn.1673-4114.2015.03.003]
[10]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
　Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[11]亓龙,王辉.甲状腺癌骨转移模型的研究[J].国际放射医学核医学杂志,2010,34(6):329.[doi:10.3760/cma.j.issn.1673-4114,2010.06.003]
　QI Long,WANG Hui.Research progress of animal model of bone metastases of thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):329.[doi:10.3760/cma.j.issn.1673-4114,2010.06.003]
[12]陈志军,谭丽玲,王文俊,等.131I联合125I粒子治疗难治性甲状腺癌骨转移一例[J].国际放射医学核医学杂志,2017,41(1):76.[doi:10.3760/cma.j.issn.1673-4114.2017.01.015]

备注/Memo

备注/Memo:
收稿日期:2018-02-04。
通讯作者:张春银,Email:zhangchunyin345@sina.com
更新日期/Last Update: 2018-05-25